Read More

Opthea’s Phase 2B Results Of OPT-302, Anti-VEGF-C/-D “Trap” Agent Administered In Combination With Lucentis (Ranibizumab) For Wet Age-Related Macular Degeneration Have Been Published In Ophthalmology, Journal Of The American Academy Ophthalmology

The prospective, randomized, controlled Phase 2b trial of 366 treatment-naïve patients with wet AMD, demonstrated that monthly intravitreal administration of 2.0 mg OPT-302 with ranibizumab standard of care, met the

OPT

Read More

Insulet Acquires Assets Related To Bigfoot’s Pump-based Automated Insulin Delivery Technologies For $25M, Including Certain Bigfoot Patents Related To Pumps That May Be Used For Automated Insulin Delivery Therapy

The transaction further strengthens Insulet's intellectual property (IP) portfolio and provides Bigfoot with additional capital to expand its Bigfoot Unity® Diabetes Management System to more people in need of

PODD